Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Hypha Labs (FUNI) Current Deferred Revenue (2018 - 2019)

Hypha Labs filings provide 7 years of Current Deferred Revenue readings, the most recent being $500.0 for Q1 2019.

  • On a quarterly basis, Current Deferred Revenue fell 72.22% to $500.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $500.0, a 72.22% decrease, with the full-year FY2018 number at $525.0, changed N/A from a year prior.
  • Current Deferred Revenue hit $500.0 in Q1 2019 for Hypha Labs, down from $1750.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $125470.0 in Q2 2015 to a low of $500.0 in Q1 2019.
  • Median Current Deferred Revenue over the past 3 years was $2328.0 (2015), compared with a mean of $36833.3.
  • The widest YoY moves for Current Deferred Revenue: up 177.06% in 2015, down 87.58% in 2015.
  • Hypha Labs' Current Deferred Revenue stood at $2328.0 in 2015, then fell by 24.83% to $1750.0 in 2018, then tumbled by 71.43% to $500.0 in 2019.
  • The last three reported values for Current Deferred Revenue were $500.0 (Q1 2019), $1750.0 (Q4 2018), and $525.0 (Q3 2018) per Business Quant data.